Thus, we propose that Bclaf1 fosters liver cancer growth and progression through transcriptional regulation of HIF-1α and its downstream angiogenic target genes, ultimately providing potential strategies and biomarkers for optimally developing novel anti-angiogenic therapies of HCC and potentially other solid tumors. Here, HIF1A is linked to hepatocellular carcinoma.